ClinicalTrials.gg
RecruitingNCT04519905Updated Nov 2, 2021

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

An interventional study of Paclitaxel plus carboplatin and radiotherapy in Esophageal Squamous Cell Carcinoma, Chemoradiotherapy and Survival, sponsored by Fudan University. Recruiting at 3 sites in China. Open to participants aged 76 Years and older. Per ClinicalTrials.gov, last updated 2021-11-02.

Sponsored by Fudan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Jan 2020, registered Aug 2020).
  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
76 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing paclitaxel in Esophageal Squamous Cell Carcinoma — 10 open to participants now, 14 under way, 3 of them phase 3. Paclitaxel · Esophageal Squamous Cell Carcinoma.

Planned enrollment
6th of 39
320 · median 56
Started
2020
with 3 others
No phase
Only one
of the 43
Primary completion
2024-12
later than 4 of 13 live
Registered
32nd of 43
by date
Lead sponsor
6 of 43
Fudan University

Among the 43 studies testing paclitaxel in Esophageal Squamous Cell Carcinoma, this one is the 6th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2020, is the only one with no phase, reaches primary completion later than 4 of the 13 other live ones, and was the 32nd registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

10 of the 43 studies testing paclitaxel in Esophageal Squamous Cell Carcinoma are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 76 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing paclitaxel in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

So far, there is no specific clinical guideline for elderly patients (>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx) or the chemoradiotherapy group (50.4Gy/28Fx;Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.

Read the detailed description

Up to now, definitive radiotherapy was major treatment plan for elderly ESCC patients. However, whether elective elderly patients can obtain survival benefits through chemoradiotherapy is not clear. Thus we design the clinical trail to answer the question.

Three hundred and twenty elderly patients with ESCC would be recruited. There are two stratification factors including 80 years old and lymph node metastasis. The patients in the chemoradiotherapy group were treated with paclitaxel (45mg/m2) and carboplatin (AUC=2) one cycle per week for five cycles.The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival. The life quality questionnaire included QlQ-C30 and OES-18.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
  • Chemoradiotherapy
  • Survival

Keywords

  • esophageal squamous cell carcinoma
  • elderly patients
  • chemoradiotherapy
  • definitive radiotherapy
  • survival
04

Who can participate

Ages eligible
76 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Indicates no limit on eligibility based on the sex of participants
  • The 76 years old for the minimum age a potential participant must meet to be eligible for the clinical study.
  • Esophageal squamous cell carcinoma confirmed by pathology
  • No radiotherapy, chemotherapy or other treatments prior to enrollment
  • Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, TxNxM1b (M1b only for supraclavicular lymph node ) (AJCC 6th)
  • Use of an effective for adults to prevent pregnancy
  • No severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function
  • No immunodeficiency
  • 0-1.
  • of more than 3 months.

Exclusion criteria

Exclusion Criteria:

  • Total radiotherapy dose cannot reach 61.2Gy/34Fx
  • Esophageal perforation, or hematemesis
  • History of radiotherapy or chemotherapy for esophageal cancer
  • History of surgery within 28 days before Day 1
  • History of prior (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years)
  • Participation in other interventional clinical trials within 30 days
  • Pregnant or breast-feeding women or fertile patients
  • Drug addiction,
  • alcoholism or AIDS
  • Uncontrolled seizures or psychiatric disorders
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    chemoradiotherapy

    50.4Gy/28Fx; Paclitaxel plus carboplatin

    Drug: Paclitaxel plus carboplatin · Radiation: radiotherapy

  • Active comparator
    radiotherapy

    61.2Gy/34Fx

    Radiation: radiotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. overall survival difference of definitive radiotherapy and chemoradiotherapy groups

    The time between the start of the study treatment (Day 1) and death from any cause or last follow-up for patients alive at the end of the study.

    Time frame: 3-year

Secondary outcomes

  1. difference of quality of life between different groups

    Assess the quality of life through life quality questionnaire.

    Time frame: the period of treatment within 7 weeks and follow up time with an average of 3months

  2. radiation side effects

    Record the radiation side effects including acute and late side effects.

    Time frame: acute side effects within 3 months, late side effects for 3 months later

  3. cancer specific survival

    The time between the start of the study treatment (Day 1) and death from tumor or last follow-up for patients alive at the end of the study.

    Time frame: 3-year

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Dec 2024, 59 months after the start.

Of 37 interventional studies with no phase under Esophageal Squamous Cell Carcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2020
First posted
Aug 20, 2020
StartActual
Jan 6, 2020
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2027
Last update
Nov 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04519905
Lead sponsor
Fudan University
Collaborators
Huadong Hospital, Jiangsu Cancer Institute & Hospital, Gansu Cancer Hospital, The First Affiliated Hospital of Xiamen University, Fujian Cancer Hospital, Taihe Hospital, Wuxi No. 4 People's Hospital, Ningbo No.2 Hospital
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Jan 6, 2020
Primary completion
Dec 2024 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 2, 2021

Study contacts

Kuaile Zhao, doctor
Contact
kuaile_z@sina.com
18017312534 ext. 021-64175590
ying jia Deng, doctor
Contact
dengjiaying3@sina.com
18017312829
Kuaile Zhao, doctor
study chair · Fudan University
Xiangpeng Zheng, doctor
principal investigator · Huadong Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Carboplatin

Start the discussion